NIH-funded research R01 grant

Preventing colorectal cancer in patients with Lynch Syndrome using immune strategies

Official title: Cancer Immune-Interception for Lynch Syndrome

Funded at University of Tx Md Anderson Can Ctr · NIH-10923965 · Data updated 2026-11-12

This study is looking at how we can use the body's immune system to help prevent colorectal cancer in people with Lynch Syndrome by finding specific markers from genetic changes and testing a medication called naproxen to boost immune responses in the colon.

More Lynch Syndrome research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Tx Md Anderson Can Ctr
NIH-funded
Lab location1 site (Houston, United States)
Project startSeptember 21, 2021
Project endAugust 31, 2026
Funding year2024
Award (this year)$639,370
NIH project number5R01CA257375-04
Project IDNIH-10923965 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with Lynch Syndrome who are at high risk for developing colorectal cancer.

Less likely to help

Patients without Lynch Syndrome or those who have already developed advanced colorectal cancer may not benefit from this research.

What this research studies

This research focuses on Lynch Syndrome, a hereditary condition that significantly increases the risk of colorectal cancer. It investigates how the immune system can be harnessed to prevent cancer in patients with this syndrome by identifying specific neoantigens that arise from genetic mutations. The study aims to enhance the immune response through the use of chemopreventive agents like naproxen, which may activate immune cells in the colorectal area. By analyzing genomic data from pre-cancerous lesions, the research seeks to develop targeted immune-interception strategies.

Why it matters

Potential benefit: If successful, this research could lead to new preventive treatments for colorectal cancer in individuals with Lynch Syndrome.

How similar studies have gone: Previous research has shown promise in using immune strategies for cancer prevention, particularly in genetically predisposed populations, indicating potential success for this approach.

Where this research is happening

  • University of Tx Md Anderson Can Ctr
    Houston, United States
    Active

Researchers

  • Principal investigator: Vilar Sanchez, Eduardo — University of Tx Md Anderson Can Ctr
  • Study coordinator: Vilar Sanchez, Eduardo

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.